BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1149 related articles for article (PubMed ID: 24766435)

  • 41. Detection of a subset of CD30+ anaplastic large cell lymphoma by interphase fluorescence in situ hybridization.
    Shin HJ; Thorson P; Gu J; Katz RL
    Diagn Cytopathol; 2003 Aug; 29(2):61-6. PubMed ID: 12889041
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
    Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
    Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
    Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?
    Fornari A; Piva R; Chiarle R; Novero D; Inghirami G
    Hematol Oncol; 2009 Dec; 27(4):161-70. PubMed ID: 19358142
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management.
    Bennani-Baiti N; Ansell S; Feldman AL
    Expert Rev Hematol; 2016; 9(2):137-50. PubMed ID: 26581318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.
    Wang R; Li L; Duan A; Li Y; Liu X; Miao Q; Gong J; Zhen Y
    Cancer Lett; 2019 Apr; 448():84-93. PubMed ID: 30742941
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).
    Colleoni GW; Bridge JA; Garicochea B; Liu J; Filippa DA; Ladanyi M
    Am J Pathol; 2000 Mar; 156(3):781-9. PubMed ID: 10702393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunohistopathological features of anaplastic large-cell lymphoma according to anaplastic lymphoma kinase expression and bone marrow involvement pattern.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ
    Histopathology; 2013 Jul; 63(1):13-8. PubMed ID: 23656317
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.
    Al-Rohil RN; Torres-Cabala CA; Patel A; Tetzlaff MT; Ivan D; Nagarajan P; Curry JL; Miranda RN; Duvic M; Prieto VG; Aung PP
    J Cutan Pathol; 2016 Dec; 43(12):1161-1166. PubMed ID: 27531242
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.
    Ceccon M; Mologni L; Giudici G; Piazza R; Pirola A; Fontana D; Gambacorti-Passerini C
    Mol Cancer Res; 2015 Apr; 13(4):775-83. PubMed ID: 25421750
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions.
    Elmberger PG; Lozano MD; Weisenburger DD; Sanger W; Chan WC
    Blood; 1995 Nov; 86(9):3517-21. PubMed ID: 7579458
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ALK-positive (2p23 rearranged) anaplastic large cell lymphoma with localization to the skin in a pediatric patient.
    Pulitzer M; Ogunrinade O; Lin O; Steinherz P
    J Cutan Pathol; 2015 Mar; 42(3):182-187. PubMed ID: 25404214
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.
    Eckerle S; Brune V; Döring C; Tiacci E; Bohle V; Sundström C; Kodet R; Paulli M; Falini B; Klapper W; Chaubert AB; Willenbrock K; Metzler D; Bräuninger A; Küppers R; Hansmann ML
    Leukemia; 2009 Nov; 23(11):2129-38. PubMed ID: 19657361
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis.
    Mussolin L; Damm-Welk C; Pillon M; Zimmermann M; Franceschetto G; Pulford K; Reiter A; Rosolen A; Woessmann W
    Leukemia; 2013 Feb; 27(2):416-22. PubMed ID: 22907048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of NPM-ALK DNA rearrangement in CD30 positive anaplastic large cell lymphoma.
    Waggott W; Lo YM; Bastard C; Gatter KC; Leroux D; Mason DY; Boultwood J; Wainscoat JS
    Br J Haematol; 1995 Apr; 89(4):905-7. PubMed ID: 7772531
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.
    Mehrotra M; Medeiros LJ; Luthra R; Sargent RL; Yao H; Barkoh BA; Singh R; Patel KP
    Hum Pathol; 2014 Oct; 45(10):1995-2005. PubMed ID: 25128227
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology.
    Jaffe ES
    Mod Pathol; 2001 Mar; 14(3):219-28. PubMed ID: 11266530
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recurrent ALK-negative anaplastic large T-cell lymphoma presenting as necrotizing vasculitis.
    Nambudiri VE; Aboutalebi A; Granter SR; Saavedra A
    Am J Dermatopathol; 2013 Jun; 35(4):512-6. PubMed ID: 23291583
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HuR-mediated control of C/EBPbeta mRNA stability and translation in ALK-positive anaplastic large cell lymphomas.
    Bergalet J; Fawal M; Lopez C; Desjobert C; Lamant L; Delsol G; Morello D; Espinos E
    Mol Cancer Res; 2011 Apr; 9(4):485-96. PubMed ID: 21343335
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
    Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G;
    Oncotarget; 2016 Nov; 7(48):79637-79653. PubMed ID: 27793034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.